Soufflé Therapeutics Secures $135M Series B to Propel RNA Delivery Trials

Soufflé Therapeutics, a Boston-area biotechnology company, has announced an oversubscribed $135M Series B funding round aimed at advancing its RNA delivery trials in muscle and heart tissue. This financing, which was led by the Juvia Group, comes at a pivotal time for the company as clinical enrollment for its trials has already begun in 2026.

The funds raised will support three lead clinical programs and further preclinical development, a strategic move that positions Soufflé to extend RNA delivery beyond the liver—a significant leap in the biotechnology sector. The company utilizes a unique approach known as REMEDY (Receptor Mediated Delivery), which focuses on identifying specific receptors that facilitate the delivery of oligonucleotide therapies into targeted cells. This methodology is crucial for ensuring that the therapies reach their intended destinations, thereby enhancing their efficacy.

In addition to Juvia Group, a notable syndicate of investors has joined this round, including TCG Crossover Management, BB Biotech, Fidelity Management & Research Company, and others. Notably, several returning investors from previous rounds, such as Amgen Ventures and Bessemer Venture Partners, have also contributed, reinforcing their commitment to Soufflé's ambitious goals.

Soufflé's most advanced clinical program targets facioscapulohumeral muscular dystrophy (FSHD), focusing on delivering therapies to striated muscle. A second program aims at addressing heart failure through targeting the phospholamban gene in cardiomyocytes, while a third program is dedicated to an undisclosed target for muscle and metabolic disorders. The intricacies of these programs highlight the complex nature of RNA therapy development and the critical need for specialized delivery mechanisms.

The company's innovative approach to drug design, which integrates tissue selection into the therapeutic process from the outset, is expected to set it apart in a competitive landscape. As clinical trials progress, the insights gained will be invaluable, not only for Soufflé’s development plans but also for the broader field of RNA therapeutics.

While the announcement did not disclose individual check sizes or a company valuation, it is evident that the backing from a robust investor group provides a solid foundation for Soufflé as it navigates the challenges of clinical development. With a focus on both immediate clinical applications and long-term research objectives, Soufflé Therapeutics is poised to make significant advancements in the field of RNA delivery.